E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

The purpose of this study is to determine the following: 1. Find the maximum tolerated dose of E7050 when given in combination with cisplatin and capecitabine in patients with advance or metastatic solid tumors, and 2) Whether E7050 in combination with cisplatin and capecitabine is more effective in patients with previously untreated gastric cancer versus cisplatin and capecitabine alone.

Study Overview

• Status: Terminated
• Conditions: Advanced or Metastatic Solid Tumors; Previously Untreated Gastric Cancer
• Intervention / Treatment: Drug: E7050; Drug: cisplatin; Drug: capecitabine

Detailed Description

This open-label, multicenter, randomized study will consist of 2 phases:

Phase Ib: a safety run-in period with 3 ascending doses of E7050 in combination with fixed doses of Cisplatin and Capecitabine. This phase will enroll approximately 10 to 15 patients.

• Phase II: a randomized 2-arm design which will enroll 80 patients.

In the phase II portion, Patients will receive study treatment , E7050 in combination with Cisplatin and Capecitabine versus Cisplatin and Capecitabine Alone) for approximately six 21-day cycles (18 weeks). Beyond 18 weeks, patients who are experiencing clinical benefit may continue E7050, with or without Capecitabine (Arm 1), or may continue Capecitabine alone (Arm 2), depending on the original randomization treatment arm. Patients will continue treatment for as long as clinical benefit is sustained and the treatment is well tolerated, until the occurrence of progressive disease (PD), unacceptable toxicity, withdrawal of consent, or withdrawal by investigator, whichever occurs first. Patients will participate in either phase Ib or phase II.

• Study Type: Interventional
• Enrollment (Actual): 7
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Russian Federation
  • Chelyabinsk, Russian Federation, 454087
    • Chelyabinsk Regional Oncology Dispensary
  • St Petersburg, Russian Federation, 195067
    • GOU VPO St-Petersburg SMA n/a Mechnikov Fed. Agen. of Healthcare and Social Developm.
  • St Petersburg, Russian Federation, 197758
    • FSI "SRC of Oncology n. a. N.N.Petrov of Rosmedtekhnologiy"
• Ukraine
  • Dnipropetrovsk, Ukraine, 49102
    • SI Dnipropetrovsk Medical Academy of MOHU ch of Oncology and Medical Radiology
  • Donetsk, Ukraine, 83092
    • Municipal Clinical Medical and Prophylactic Institution Donetsk Regional Antitumor Centre
  • Kyiv, Ukraine, 3115
    • Kyiv City Clinical Oncological Center
  • Lviv, Ukraine, 79031
    • Lviv State Oncol. Reg. Treatment and Diagnostic Center
• United Kingdom
  • Greater London
    • London, Greater London, United Kingdom, EC1A 7BE
      • Barts and The London NHS Trust
    • London, Greater London, United Kingdom, W1G 6AD
      • Sarah Cannon Research UK
  • Greater Manchester
    • Manchester, Greater Manchester, United Kingdom, M20 4BX
      • The Christie NHS Foundation Trust
• United States
  • Arizona
    • Tucson, Arizona, United States, 85715
      • Arizona Oncology Associates, PC - CASA
  • Florida
    • Plantation, Florida, United States, 33324
      • Boca Raton Clinical Research Associates, Inc
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Robert H. Lurie Comprenhensive Cancer Center of Northwestern University
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • University of Michigan Comprehensive Cancer Center
    • Detroit, Michigan, United States, 48202
      • Henry Ford Medical Center
    • Detroit, Michigan, United States, 48084
      • Barbara Ann Karmanos Cancer Institute
  • North Carolina
    • Chapell Hill, North Carolina, United States, 27599
      • University of North Carolina at Chapel Hill
    • Durham, North Carolina, United States, 27710
      • Duke University Medical Center
  • Ohio
    • Toledo, Ohio, United States, 43623
      • Mercy Cancer Centerr at St. Anne

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria

• Histologically confirmed, unresectable, locally advanced or metastatic gastric cancer, including adenocarcinoma of the gastroesophageal junction (Phase II). For the Phase Ib portion, any unresectable, locally advanced or metastatic solid tumor;
• ECOG PS of 0-1;
• Blood pressure must be well-controlled. Patients must have no history of hypertensive crisis or hypertensive encephalopathy; Adequate end organ function

Exclusion Criteria

• Gastric cancer patients who have had a complete gastrectomy;
• Patients with known HER2 over-expressing advanced or metastatic gastric cancer;
• Previously received E7050, its chemical derivatives, anti-cMet, anti-angiogenic therapy, (prior anti-angiogenic therapy is permitted in Phase Ib only).
• For Phase Ib prior systemic therapy is allowed as long as PS and end organ function meet entry criteria;
• For Phase II no prior palliative chemotherapy is permitted. Adjuvant/neoadjuvant chemotherapy is permitted if less than 12 months have elapsed between the end of adjuvant/neoadjuvant therapy and first recurrence;
• Known central nervous system lesions, except for asymptomatic non-progressing, treated brain metastases. Treatment for brain mets, but have been completed at least 4 weeks prior to Day 1
• Palliative radiotherapy is not permitted throughout the study period. Prior palliative radiotherapy within 30 days prior to commencing study treatment;
• Clinically significant hemoptysis;
• Patients with known dihydropyrimidine dehydrogenase deficiency;
• Patients with clinically significant hearing loss that may be further diminished by treatment with cisplatin plus capecitabine (significance of hearing loss to be determined by the Investigator;
• Serious non-healing wound, ulcer, or active bone fracture;
• Major surgical procedure, open biopsy, or significant traumatic injury within the 21 days prior to commencing study treatment;
• Clinically significant gastrointestinal bleeding within 6 months prior to first dose.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Phase Ib: Cohort 1 and 2 and 3; Phase Ib: Cohort 1; 200 mg E7050 + 80 mg/m2 cisplatin + 1000 mg/m2 capecitabine Cohort 2; 300 mg E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine Cohort 3; 400 mg E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine	Drug: E7050; E7050 given orally at either 200, 300, or 400 mg once daily.; Drug: cisplatin; Cisplatin will be administered at 80 mg/m2 by intravenous infusion over 60 minutes on Day 1 of each 21-day treatment cycle.; Drug: capecitabine; Capecitabine will be administered at 1000 mg/m2 orally, twice daily (2000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.
Active Comparator: Phase II: Arm 1; E7050 + cisplatin+ capecitabine; Phase II: Arm 1; MTD E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine	Drug: E7050; E7050 given orally at either 200, 300, or 400 mg once daily.; Drug: cisplatin; Cisplatin will be administered at 80 mg/m2 by intravenous infusion over 60 minutes on Day 1 of each 21-day treatment cycle.; Drug: capecitabine; Capecitabine will be administered at 1000 mg/m2 orally, twice daily (2000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area Under The Concentration-Time Curve (AUC) From 0 to 24 Hours of Golvatinib	On days when pharmacokinetic (PK) samples were to be drawn, a predose blood sample was obtained prior to administration of golvatinib and capecitabine. After administration of study drugs, a second postdose blood sample was taken. The amount of golvatinib in the participant's blood was analyzed and the AUC was calculated. The AUC reflects the actual body exposure to drug after administration of a dose of the drug and is dependent on the rate of elimination of the drug from the body and the dose administered. Predose samples that were below the limit of quantitation (BLQ) or missing were assigned a numerical value of zero for the calculation of AUC. Any other BLQ concentrations were assigned a value of zero. Results were expressed in nanograms·hour/milliter (ng·h/mL).	Cycle 1 (Day -2); predose, 30 minutes, 1, 2, 3, 4, 8, 12 (if feasible), 24, and 48 hours after study treatment. Cycle 2 (Day 1); predose, 30 minutes, 1, 2, 3, 4, 8, 12 (if feasible), and 24 hours after study treatment.
Maximum Concentration (Cmax) of Golvatinib	Blood samples were drawn to analyze the amount of golvatinib in the participant's serum. Maximum concentration refers to the maximum (or peak) serum concentration of study drug in the participant's system after administration of the study drug and prior to the administration of a second dose of the study drug. Results were expressed in nanograms/milliliter (ng/mL).	Cycle 1 (Day -2); predose, 30 minutes, 1, 2, 3, 4, 8, 12 (if feasible), 24, and 48 hours after study treatment. Cycle 2 (Day 1); predose, 30 minutes, 1, 2, 3, 4, 8, 12 (if feasible), and 24 hours after study treatment.
Number of Participants With a Treatment-Emergent Adverse Event (TEAE)	Safety assessments consisted of monitoring and recording all adverse events (AEs) and serious AEs; regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs and electrocardiograms (ECGs); and performance of physical examinations. A TEAE was defined as an adverse event (AE) that had an onset date, or a worsening in severity from Baseline (pretreatment), on or after the first dose of study drug up to 30 days after the date of last study treatment.	From date of first dose up to 30 days after the last dose of study treatment, up to approximately 1 year 1 month.
Time to Maximum Concentration (Tmax) of Golvatinib	Tmax was defined as the time at which Cmax was observed for golvatinib in combination with cisplatin and capecitabine.	Cycle 1 (Day -2); predose, 30 minutes, 1, 2, 3, 4, 8, 12 (if feasible), 24, and 48 hours after study treatment. Cycle 2 (Day 1); predose, 30 minutes, 1, 2, 3, 4, 8, 12 (if feasible), and 24 hours after study treatment.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Response Rate (ORR)	The study was terminated prior to enrollment in Phase 2 so this outcome measure was not conducted.	Until disease progression or death for 3 years
Time to Progression (TTP)	The study was terminated prior to enrollment in Phase 2 so this outcome measure was not conducted.	Until disease progression or death for 3 years

Collaborators and Investigators

• Sponsor: Eisai Inc.
• Collaborators: Quintiles, Inc.
• Investigators: Study Director: Melissa Versola, Quintiles, Inc.

Study record dates

Study Major Dates

• Study Start: November 1, 2011
• Primary Completion (Actual): April 1, 2013
• Study Completion (Actual): July 1, 2013

Study Registration Dates

• First Submitted: May 16, 2011
• First Submitted That Met QC Criteria: May 17, 2011
• First Posted (Estimate): May 18, 2011

Study Record Updates

• Last Update Posted (Actual): May 15, 2017
• Last Update Submitted That Met QC Criteria: April 7, 2017
• Last Verified: March 1, 2017

More Information

Terms related to this study

• Keywords: Cancer; Phase I; Phase II; Solid Tumors; Gastric
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Stomach Diseases; Stomach Neoplasms; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Cisplatin; Capecitabine
• Other Study ID Numbers: E7050-703; 2011-000774-58 (EudraCT Number)